BevCanna Enterprises

CANNABICS PHARMACEUTICALS OTCMKTSCNBX STOCK QUOTE

https://cannabics.com/

LATEST NEWS FROM CANNABICS PHARMACEUTICALS

Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine

Hemato-Oncology Expert, Dr. Sigal Tavor (MD) Joins Cannabics Pharmaceuticals' Board of Advisors

World-Renowned Melanoma Expert Joins Cannabics Pharmaceuticals' Board of Advisors

Cannabics Pharmaceuticals Appoints a Second Independent Board Member

Cannabics Pharmaceuticals Announces Appointment of New Independent Board Member

Cannabics Pharmaceuticals' Drug Candidate Exhibits 30% Tumor Volume Reduction in Mice

Cannabics Pharmaceuticals to launch Drug Development Programs for Prostate Cancer and Neurodegenerative & Mental Health Diseases

Cannabics Pharmaceuticals Launches a Breast Cancer Treatment Research Program

The European Patent Office Grants Cannabics Pharmaceuticals Patent for Company's Personalized Medicine Drug Discovery Technology

Cannabics Pharmaceuticals Files a PCT Patent Application for Proprietary Cancer Treatment Formulations

Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)

Cannabics Pharmaceuticals Launches a New Research Program to develop a Melanoma Treatment Drug Candidate for FDA Approval Track

Cannabics Pharmaceuticals Launches Psilocybin and Psilocin Research Program

Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33

Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells

Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016

Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer

Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer